science2 publishers
Del-desiran missed on a hand-opening time that clinical experts score from video
Novartis says it saw evidence of clinical activity in secondary and exploratory analyses it has not disclosed, while the drug missed its primary endpoint, an expert-rated video timing of hand opening. Shares fell 11% in Zurich.
Reality
- Evidence64
- Adoption15
- Hype gap+30
- Incentives80
- Confidence72